CLINICALLY SIGNIFICANT EBV DNAEMIA

Clinical trials for CLINICALLY SIGNIFICANT EBV DNAEMIA explained in plain language.

Never miss a new study

Get alerted when new CLINICALLY SIGNIFICANT EBV DNAEMIA trials appear

Sign up with your email to follow new studies for CLINICALLY SIGNIFICANT EBV DNAEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Could a simple drug infusion stop a dangerous virus after stem cell transplants?

Disease control Not yet recruiting

This trial investigates whether giving two low doses of rituximab shortly after a stem cell transplant can prevent serious Epstein-Barr virus (EBV) infections. Participants are adults aged 16-65 who have received a donor stem cell transplant and are at medium-to-high risk for EBV…

Matched conditions: CLINICALLY SIGNIFICANT EBV DNAEMIA

Phase: NA • Sponsor: Yang Donglin • Aim: Disease control

Last updated Jul 16, 2026 00:00 UTC

CLINICALLY SIGNIFICANT EBV DNAEMIA

Get alerted when new CLINICALLY SIGNIFICANT EBV DNAEMIA trials appear

Could a simple drug infusion stop a dangerous virus after stem cell transplants?